Trial Profile
Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of Butylated Hydroxytoluene Via Respimat Soft MistTM Inhaler B (Sub-study 1) and Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of BI 54903 XX Via Respimat Soft MistTM Inhaler B as Randomised, Double-blind, Placebo-controlled Phase I Trial in Healthy Male Volunteers (Main Study) and Comparison of Systemic Exposure Following a Single Dose of BI 54903 XX Via Respimat Soft MistTM Inhaler B and of a Single Dose of Ciclesonide Via MDI (Randomised, Open-label, Two-way Crossover Sub-study 2)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 54903 (Primary) ; Ciclesonide
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 23 Aug 2014 New trial record